Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.8 - $13.17 $167,200 - $250,230
19,000 Added 678.57%
21,800 $218,000
Q1 2024

May 15, 2024

SELL
$11.47 - $16.17 $310,837 - $438,207
-27,100 Reduced 90.64%
2,800 $34,000
Q4 2023

Feb 14, 2024

BUY
$7.06 - $14.49 $93,192 - $191,268
13,200 Added 79.04%
29,900 $427,000
Q3 2023

Nov 14, 2023

SELL
$7.43 - $14.96 $592,171 - $1.19 Million
-79,700 Reduced 82.68%
16,700 $129,000
Q2 2023

Aug 14, 2023

SELL
$11.63 - $15.63 $698,963 - $939,363
-60,100 Reduced 38.4%
96,400 $1.38 Million
Q1 2023

May 15, 2023

BUY
$12.54 - $19.38 $1.02 Million - $1.57 Million
81,100 Added 107.56%
156,500 $2.29 Million
Q4 2022

Feb 14, 2023

SELL
$13.77 - $22.04 $1.58 Million - $2.53 Million
-114,900 Reduced 60.38%
75,400 $1.27 Million
Q3 2022

Nov 14, 2022

BUY
$13.74 - $30.13 $1.57 Million - $3.43 Million
114,000 Added 149.41%
190,300 $2.82 Million

Others Institutions Holding OPRX

About OptimizeRx Corp


  • Ticker OPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Health Information Services
  • Shares Outstandng 18,023,100
  • Market Cap $140M
  • Description
  • OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patien...
More about OPRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.